| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 30, 2026 | Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist | CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, wi... |
| Sep 17, 2026 | Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study | The paper introduces three interconnected resources for the global scientific community:
LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology;
Longevity-LLMs, a famil... |
| Sep 7, 2026 | Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks | First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment).
Firs... |
| Jul 16, 2026 | Edgewise closes muscular-dystrophy biz sale in deal that could top $2.6M | Getting your Trinity Audio player ready...
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) recently closed on a deal — one that could eventually be worth $2.65 billion and includes a drug pipeline led by sevasemten — that sends its musc... |
| Jul 14, 2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| Jul 13, 2026 | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.
The acquired asset and expert team strengthen Servier's commitment to ... |
| Jul 9, 2026 | Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 | CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof... |
| Jun 24, 2026 | Great Place To Work Reveals Southeast Asia's Best Workplaces™ in Healthcare & Biopharma | SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honou... |
| Jun 10, 2026 | Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders | Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world.
... |
| Jun 5, 2026 | Operator of S&P 500 decides against fast-tracking ‘MegaCap’ IPOs into its stock indexes | Getting your Trinity Audio player ready...
By ALEX VEIGA, AP Business Writer
The operator of the S&P 500 says it has decided not to change its guidelines for when very large “MegaCap” companies are eligible for inclusion into its bevy o... |
| Jun 5, 2026 | First-time homebuyers face hurdles despite gradual improvement | Getting your Trinity Audio player ready...
By Tim Henderson, Stateline.org
The idea started with a sermon Micah Longmire heard at his Presbyterian church in Ogden, Utah, about the importance of grandparents in a child’s life.
Longmire, now ... |
| Jun 5, 2026 | Some Broomfield ballot drop-off boxes to be closed during primary election | Getting your Trinity Audio player ready...
In Broomfield, four of the city’s seven ballot drop-off box locations will be closed for the upcoming primary election for surveillance equipment replacement, according to city officials.
Broomfiel... |
| Jun 5, 2026 | French pharma giant Servier buys Edgewise muscular dystrophy biz | Getting your Trinity Audio player ready...
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has offloaded its muscular-dystrophy business, which includes a drug pipeline led by sevasemten, to France-based international pharmaceutical com... |
| May 5, 2026 | Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, a... |
| Apr 23, 2026 | Servier completes the acquisition of Day One Biopharmaceuticals | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma.
Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unme... |
| Mar 7, 2026 | Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs.
Transaction represents total equity value of approximately $2.5 bill... |
| Mar 3, 2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| Feb 17, 2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| Feb 6, 2026 | Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology | CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, Ph... |
| Jan 27, 2026 | Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030 | Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24.
Growth over the financial year was driven by increased sales in oncology, particularly in the United States.
Several partnership agreements in oncology and ... |
| Jan 9, 2026 | 3 new venture funds collect nearly $1B for biotech in US, EU | The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z).
The Silicon Valley-based venture capitalist announced $15 billion raised across its separate venture strategy areas, with ... |
| Jan 5, 2026 | Insilico Medicine And Servier Announce Up To $888 Million Multi-Year Oncology Drug Discovery Collaboration | Insilico Medicine announced it has entered a multi-year research and development collaboration with Servier focused on discovering and developing novel oncology therapies, combining Insilico’s AI-driven drug discovery platform, Pharma.AI, w... |
| Dec 12, 2025 | Болезням прописали инструкцию | |
| Dec 8, 2025 | Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions | Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases.
These awards across several geographies recognize the progress represented by Voranigo® for... |
| Dec 5, 2025 | Indo-French CSR Excellence Celebrated at IFCCI's 7th Annual CSR Conclave & Awards | New Delhi, Delhi, India
The 7th edition of the CSR Conclave and Awards, organised by the Indo-French Chamber of Commerce and Industry (IFCCI), was held on 2nd December at ITC Maurya, New Delhi, in the presence of Mr Damien Syed, Deputy Head... |
| Sep 9, 2025 | Whatfix Launches AI Agents to Accelerate Business Outcomes for Enterprises | Bengaluru, Karnataka, India
Whatfix, the global leader in digital adoption platforms (DAP), today announced the launch of Whatfix AI Agents embedded across its product suite to accelerate user productivity and drive business performance out... |
| Sep 9, 2025 | Whatfix Launches AI Agents to Accelerate Business Outcomes for Enterprises | Whatfix AI Agents leverage ScreenSense — the company's context- and intent-aware AI technology — to accelerate workflows and drive user productivity.
SAN JOSE, Calif., Sept. 9, 2025 /PRNewswire/ -- Whatfix, the global leader in digital adop... |
| Sep 8, 2025 | Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder | Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company
KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug De... |
| Aug 27, 2025 | QC Ware Announces 3rd Q2B Paris Conference Focused on the Roadmap to Quantum Value in Europe and Beyond, Quandela to Sponsor | QC Ware and Bpifrance to host, under the high patronage of Mr. Emmanuel MACRON, President of the French Republic, the 2025 Q2B Paris Conference to connect international and European quantum industry experts across pharmaceutical, finance, t... |
| Apr 2, 2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| Feb 18, 2025 | IT Leaders Forum 2025: Shaping the Future of Business and Technology in Africa | JOHANNESBURG, SOUTH AFRICA – Media OutReach Newswire – 18 February 2025 – IT News Africa is proud to announce the IT Leaders Forum 2025, a premier gathering of top technology and information industry experts. The event is set to take place ... |
| Feb 5, 2025 | ECTFE: The New Vanguard in Chemical Transport | In the world of industrial piping, the stakes are high. The transport of aggressive chemicals is akin to navigating a minefield. One wrong move, and the consequences can be catastrophic. Traditional materials like PFA and stainless steel ha... |
| Feb 4, 2025 | Lundbeck announces changes to the Board of Directors | Lundbeck announces changes to the Board of Directors
Tue, Feb 04, 2025 17:10 CET Report this content
Lundbeck announces changes to the Board of Directors Lars Søren Rasmussen, Chair of Lundbeck’s Board of Directors, has decided not to seek ... |
| Jan 15, 2025 | The Pulse of Workplace Excellence: A Deep Dive into the Best Places to Work for 2024 | In the ever-evolving landscape of employment, the quest for the best workplace is akin to searching for a hidden gem. The Best Places to Work rankings for 2024 have emerged, shining a spotlight on organizations that not only excel in their ... |
| Jan 14, 2025 | The world’s 30 Best Places to Work for 2024 revealed | NEW YORK, USA – Media OutReach Newswire – 14 January 2025 – The highly anticipated Best Places to Work World Rankings for 2024 have been revealed, showcasing 30 leading organizations from various industries and regions that have demonstrate... |
| Jan 7, 2025 | Top 25 Best Places to Work in Europe for 2024 revealed | LONDON, UNITED KINGDOM – Media OutReach Newswire – 7 January 2025 – The Best Places to Work organization is proud to announce the Top 25 Best Places to Work in Europe for 2024, recognizing the most outstanding employers who have demonstrate... |
| Dec 6, 2024 | A New Era for GitLab: Bill Staple's Leadership Amidst Change | On December 5, 2024, GitLab announced a significant leadership change. Bill Staple stepped into the role of CEO, replacing Sid Sijbrandij, who has led the company since 2012. This transition is not just a change of guard; it symbolizes a ne... |
| Dec 6, 2024 | Great Place To Work™ Greater China Celebrates Diversity, Equity, and Inclusion at 2024 Conference and Awards Ceremony | SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- Great Place to Work™ Greater China successfully hosted its 2024 Conference and Awards Ceremony on December 5 at The Peninsula, Shanghai. This prestigious event brought together 200 leaders, HR professi... |
| Oct 10, 2024 | IT Leaders Forum 2024 Gathers Top IT Decision-Makers for Insights on Resilience and Innovation | JOHANNESBURG, SOUTH AFRICA – Media OutReach Newswire – 10 October 2024 – IT News Africa is excited to announce IT Leaders Forum 2024, which will take place on November 5, 2024, at The Capital Empire in Sandton, South Africa. This premier ev... |
| Aug 6, 2024 | Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma | VORANIGO is the first and only FDA-approved targeted treatment in Grade 2 IDH-mutant glioma
VORANIGO demonstrated significant improvement in progression free survival with a favorable safety profile in a pivotal Phase 3 study of patients wi... |
| May 23, 2024 | Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024 | Real-world analysis shows trends of treatment patterns in newly diagnosed acute myeloid leukemia patients
Data from Phase 1/2 study evaluating ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1 ... |
| May 14, 2024 | Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey | Servier is ranked 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication and overall familiarity in the industry
BOSTON, May 14, 2024 /PRNewswire/ -- Servier, a leader in oncolog... |
| Mar 21, 2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| Dec 21, 2023 | CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore | The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights.
The deal enables Servier to potentially bring additional indications and accessibility of TIBS... |
| Sep 29, 2023 | Digitale Innovationen in der Pflege: Servier verleiht „i-care-Award“ 2023 beim Deutschen Pflegetag | Der mit einer Förderung der Preisträger versehene „i-care-Award 2023“ wurde beim zehnten Deutschen Pflegetag am 28. September 2023 in Berlin verliehen. Eine interdisziplinär zusammengesetzte Jury hat sich aus einer Fülle an Bewerbungen für ... |
| May 10, 2023 | Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma | Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapy in Europe
IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer
PARIS, May 10, 2023 /PRN... |
| May 2, 2023 | Digitale Pflege-Innovationen: Ausschreibung i-care-Award | Digitale Innovationen können den Arbeitsalltag von professionell Pflegenden entlasten und eine gute pflegerische Versorgung ermöglichen. Das internationale, private Pharmaunternehmen Servier vergibt dazu auch im Jahr 2023 die bekannte Ausze... |
| Mar 28, 2023 | Digitale Pflege-Innovationen: Ausschreibung i-care-Award | Digitale Innovationen können den Arbeitsalltag von professionell Pflegenden entlasten und eine gute pflegerische Versorgung ermöglichen. Das internationale, private Pharmaunternehmen Servier vergibt dazu auch im Jahr 2023 die bekannte Ausze... |
| Mar 14, 2023 | Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) | Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years
Endpoints met in a prespecified interim analysis
vorasidenib granted fast track designation b... |
| Mar 9, 2023 | Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio | PARIS, March 9, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain val... |
| Feb 24, 2023 | Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients | Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe
The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies
PARIS, Feb. 24, 2023 /PRNewswire/ -- Serv... |
| Feb 2, 2023 | Servier full year 2021/22 results confirm the transformation trajectory of the Group | Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales
Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, ... |
| Jan 9, 2023 | Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology | Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology.
Natural Language Processing Capabilities : Finch Computing Accelerates its Natural Language Pro... |
| Dec 11, 2022 | Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022 | New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO® (ivosidenib tablets) in combination with azacitidine in the global Phase 3 AG... |
| Oct 7, 2022 | Servier adds a 'smile' to its brand while setting ambitious oncology goals | Servier has dropped billions of dollars over the past several years with the goal of becoming a top player in hard-to-treat cancers. Now it’s setting a deadline — and giving its brand a makeover.
The French pharma aims to hit a... |
| Oct 6, 2022 | Servier unveils its 2030 ambition and reveals a new visual identity | A new ambition by 2030 to accelerate its transformation dynamic
A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal
PARIS, Oct. 6, 2022 /PRNewswire/ -- Servier today unveils its 2030 ambi... |
| Sep 29, 2022 | CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION | GENEVA, Sept. 29, 2022 /PRNewswire/ -- On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, saying millions more lives are now at risk from cardiovascular disease, which is... |
| Jul 2, 2022 | Empathy, Trust, Respect - All that your Doctor Needs | Mumbai, Maharashtra, India
In a unique effort to augment support for the selfless services of medical practitioners in the country and to support them to serve patients better, an awareness-cum-people-connect campaign was undertaken on the ... |
| May 26, 2022 | Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia | TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia
FDA approval based on data from the global, Phase 3 AGILE trial that dem... |
| Mar 23, 2022 | Digitale Innovationen in der Pflege: Servier lobt “i-care-Award” 2022 aus – Bewerbungsschluss 31. 05. 2022 | Das internationale, private Pharmaunternehmen Servier vergibt dazu auch im Jahr 2022 die bekannte Auszeichnung für Startups und junge Unternehmen, die solche digitalen Innovationen entwickeln – den „i-care-Award“. Der mit einer Förderung de... |
| Jan 18, 2022 | Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline | - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates)
- Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at... |
| Dec 13, 2021 | Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia | TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objecti... |
| Nov 5, 2021 | New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio | First Phase 3 results from the AGILE trial in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation show improved event-free survival and various secondary outcomes, including complete remission, overall survival and ob... |
| Oct 14, 2021 | Digitale Innovationen in der Pflege: Servier verleiht “i-care-Award” 2021 beim Deutschen Pflegetag | Der mit einer Förderung der Preisträger versehene „i-care-Award“ wurde im Rahmen des Deutschen Pflegetages am 13. Oktober 2021 in Berlin verliehen. Eine interdisziplinär zusammengesetzte Jury hat sich aus einer Fülle an Bewerbungen für folg... |
| Aug 2, 2021 | Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia | TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy.
Safety profile consistent with previously published data in patients with I... |
| Jul 12, 2021 | Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics | PARIS, July 12, 2021 /PRNewswire/ -- Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop R... |
| Feb 9, 2021 | Verlängert bis 31. März: Digitale Innovationen in der Pflege: Servier lobt “i-care-Award” 2021 aus | Das internationale, private Pharmaunternehmen Servier vergibt dazu im Jahr 2021 erneut die bekannte Auszeichnung für Startups und junge Unternehmen, die solche digitalen Innovationen entwickeln – den „i-care-Award“. Der mit einer Förderung ... |
| Dec 15, 2020 | Digitale Innovationen in der Pflege: Servier lobt “i-care-Award” 2021 aus | Das internationale, private Pharmaunternehmen Servier vergibt dazu im Jahr 2021 erneut die bekannte Auszeichnung für Startups und junge Unternehmen, die solche digitalen Innovationen entwickeln – den „i-care-Award“. Der mit einer Förderung ... |
| Jun 8, 2020 | Servier Closes Purchase of Symphogen | Servier, a Paris, France-based independent international pharmaceutical company, completed the acquisition of Symphogen A/S.
The amount of the deal was not disclosed.
Symphogen will now function as Servier’s antibody center of excellence ac... |
| Dec 19, 2019 | Digitale Innovationen in der Pflege: Servier lobt Preis für digitale Anwendungen auf dem Deutschen Pflegetag aus | Digitale Gesundheitsanwendungen können den Arbeitsalltag von professionell Pflegenden entlasten und eine gute pflegerische Versorgung ermöglichen. Das internationale, private Pharmaunternehmen Servier vergibt dazu im kommenden Jahr erstmals... |
| Jan 9, 2019 | WeHealth by Servier and PathMaker Neurosystems form partnership for a Breakthrough Non-Invasive Neuromodulation Device for the Treatment of Spasticity | PARIS & BOSTON–(BUSINESS WIRE)–January 9, 2019–
WeHealth by Servier, the e-health department of Servier Group, and PathMaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company, announced today the closing of a part... |
| Mar 6, 2017 | GSK vet named CEO of China CAR-T JV with Kite; Coherus fights back against Amgen claims it stole trade secrets | → Richard Wang, the former site chief for GSK in Shanghai, is taking the CEO’s job at Fosun Kite, a joint venture established by Kite Pharma and Shanghai Fosun to advance Kite’s CAR-T $KITE to the market.
→Amgen $AMGN has fil... |
| Dec 18, 2015 | Servier invests in GeNeuro | |
| Dec 2, 2014 | GeNeuro and Servier Sign $450M Agreement to Develop Multiple Sclerosis Treatment | |
| Jun 26, 2014 | MiRagen Therapeutics Raises $7M, Extends Deal with France’s Servier | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
MiRagen Therapeutics, a Boulder, CO-based drug discovery company focused on developing microRNA-targeting therapies for cardiovascular and muscle diseases, has extended its co... |
| Nov 20, 2013 | Clovis Oncology Acquires Ethical Oncology Science for up to $415M | Clovis Oncology (NASDAQ:CLVS), a Boulder, Colorado-based biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets, has acquired EOS... |
| EU-backed healthcare project rolls out platform for federated learning in drug discovery | The three-year project MELLODDY, which had received €18-million from the European Union and partnering EFPIA companies under the Innovative Medicines Initiative (IMI2), has now built a secure platform for privacy-preserving and federated le... |
| Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024 | Servier is ranked 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication, and overall familiarity in the industry*
BOSTON, May 30, 2024 /PRNewswire/ -- Servier, a leader in oncol... |
